## June 2024: Medical Policies, Coding/Reimbursement

Select Health publishes the *Policy Update Bulletin* monthly with new, revised, and archived policy information as well as policy developments and related practice management tips. **Policy updates are featured below and on page 2; coding updates are also on page 2.** 

**Questions?** Contact <u>Marcus.Call@selecthealth.org</u> for information on content of a medical policy, <u>Brandi.Luna@selecthealth.org</u> for questions about coding and reimbursement policies, or your Provider Relations representative for any other questions.

## Select Health Policy Updates

This update includes **one new policy, Tricuspid** Valve Implantation (684), found on page 95 of the <u>Cardiovascular booklet</u>. It was published on 06/14/24 with criteria.

There are **six revised policies** in this update (see **Table 1** below and on the next page).

Policies listed in **Table 1** are arranged alphabetically by title, with a link to the online specialty-based book and page number where the policy can be found (or to the policy itself if coding/reimbursement).

There are no archived policies this month.

Policies are also available on the current <u>Select Health</u> <u>Provider Portal (secure login required)</u>.

| Policy Title (Number)   | Revision Date: Summary of Change<br>(applies ONLY to Commercial plan policy unless summary text appears in BOLD)  |
|---|---|
| Gender Affirming Medical and<br>Surgical Treatment for Colorado<br>Commercial Plans (452), see<br>page 40 in the <u>General Surgery</u><br><u>booklet</u> . | <ul> <li>O6/20/2024:</li> <li>Modified title of policy to clarify this is for "Colorado Commercial Plans" instead of "Colorado-based Plans"</li> <li>Clarified a diagnosis of gender dysphoria is required for coverage of procedures listed in policy</li> <li>Added language to clarify members must be age 18 or older to qualify for related surgical treatments</li> </ul>   |
| <b>Gene Therapy, Testing, and</b><br><b>Counseling (123)</b> , see page 27 in<br>the <u>Genetic Testing booklet</u> .                                       | <ul> <li>05/24/2024: Added the following clarifying language to the Preimplantation<br/>Genetic Testing section,</li> <li>"Select Health will cover preimplantation genetic testing of up to 16 oocytes<br/>per case.</li> <li>Select Health will only cover genetic testing for aneuploidy (PGT-A) when<br/>performed in concert with PGT-M. Select Health does NOT cover preimplantation<br/>genetic testing for aneuploidy (PGT-A) separately, due to a lack of sufficient<br/>evidence supporting efficacy of this testing; this meets the plan's definition of<br/>experimental/investigational."</li> </ul> |

### **Table 1. Revised Medical Policies**



Continued on page 2...



# Policy Update Bulletin

#### ...Continued from page 1

### Table 1. Revised Policies, Continued

| Policy Title<br>(Number)   | Revision Date: Summary of Change<br>(applies ONLY to Commercial plan policy unless summary text appears in BOLD)   |
|--|--|
| Genetic Testing: Comparative<br>Genomic Hybridization<br>(CGH)/Chromosomal<br>Microarray (CMA) (297),<br>see page 94 in the <u>Genetic</u><br><u>Testing booklet</u> . | <b>05/24/2024</b> : Added criterion #B4 as a qualifying factor to coverage criteria:<br>"Recurrent pregnancy loss (beginning at second pregnancy loss)"  |
| Hypoglossal<br>Neurostimulation (Inspire<br>Upper Airway Stimulation)<br>(608), see page 30 in the<br>Pulmonary booklet.   | <b>06/14/2024</b> : Modified criterion #A2: "Moderate-to-severe OSA with AHI: 15 to 100 events per hour, and polysomnography or home sleep testing within 24 months of Inspire stimulator consult" |
| LINX System for the<br>Management of GERD<br>(520), see page 59 in the<br><u>Gastroenterology booklet</u> .  | <b>06/20/2024</b> : Revised this policy to include criteria for coverage   |
| Synthetic Bulking Agents for<br>Stress Urinary Incontinence<br>(218), see page 24 in the<br>Genitourinary booklet.   | <b>06/03/2024</b> : Added Bulkamid to list of products eligible for coverage   |

### Select Health Coding Updates

Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

For our Medicare lines of business, we have started following the Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD) L39118, effective April 1, 2024. For more information on the billing and coding guidance for this LCD, access <u>CMS Article A58867</u>.



 $\circledast$  2024 Select Health. All rights reserved. 2988402 06/24

